Eli Lilly suspends prasugrel Phase IIs

LLY was off $3.72 to $52.43 on 22.8 million shares Thursday after reporting late Wednesday that it had suspended enrollment in a pair of Phase II trials of prasugrel ( CS-747) to treat acute coronary ...